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Summary 
Background After decades of decreasing scarlet fever incidence, a dramatic increase was seen in 
England beginning in 2014. Investigations were launched to assess clinical and epidemiological 
patterns and identify potential causes. 
Methods Statutory scarlet fever notifications from 1911 onwards (England and Wales) were analysed 
to identify periods of sudden escalation. Characteristics of cases and outbreaks in England including 
frequency of complications and hospitalisations were assessed and compared to the pre-upsurge 
period. Isolates from throat swabs were collected and subjected to emm typing. 
Findings Population rates of scarlet fever increased three-fold between 2013 and 2014 from 8·2 to 
27·2 per 100,000 (RR=3·34; 95% CI 3·23-3·45); further increases in 2015 (30·6) and 2016 (33·2) 
reached the highest number (19,206 cases) and rate since 1967. Median age of cases in 2014 was 4y 
(range 0 – 90y) with rates of 186/100,000 in children under 10y. All parts of England saw an 
elevation in incidence with 620 outbreaks reported in 2016. Scarlet fever hospital admissions 
increased by 97% between 2013 and 2016; 1 in 40 cases were admitted for management of the 
condition or potential complications. Analysis of strains (n=303) identified a diversity of emm types 
with 43% emm3, 15% emm12, 11% emm1, and 9% emm4. Longitudinal analysis identified 4-yearly 
periodicity in incidence but of consistently lower magnitude than the current escalation. 
Interpretation England is experiencing an unprecedented rise in scarlet fever with the highest 
incidence for nearly 50 years. Reasons for this escalation are unclear and identifying these remains a 
public health priority. 
Funding This investigation was funded by Public Health England. 
 
KEYWORDS: Scarlet fever; Streptococcus pyogenes; Streptococcal infections/ Epidemiology; 
Streptococcal infections/ Prevention & Control; Population surveillance; Epidemics; England. 
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Research in context 
Evidence before this study  
A once common cause of childhood death, incidence and severity of scarlet fever dropped 
dramatically over the course of the nineteenth and twentieth centuries. The reasons for the decline, 
predating the advent of effective treatments, remain unexplained. Historical epidemiological patterns 
described in Europe and North America are similar to those seen in modern times with highest 
incidence rates in children but with adults also susceptible to disease. Periodicity in disease incidence 
was well described with epidemic years occurring every 4-6 years.  
 
Subsequent to a prolonged period of low incidence, a dramatic escalation in scarlet fever incidence 
was seen in England during the spring of 2014, triggering a number of investigations to assess the 
impact and identify potential drivers. We searched PubMed for studies published between January 
2000 and July 2017, with the keywords “scarlet fever” and either “epidemiology” or “surveillance” to 
identify data from other countries describing recent trends. We also searched ProMED for posts 
mentioning “scarlet fever” without date restriction. This identified sequential reports from Vietnam, 
South Korea, Hong Kong and mainland China describing sudden and widespread escalation of scarlet 
fever incidence from 2008 onwards. England is the first European country to note such a change. 
 
Added value of this study  
Our study is the first to describe the impact of a modern-day resurgence in scarlet fever. We describe 
the sudden escalation in incidence in 2014 with notifications made for 1 in 500 children under 10 
years of age. Incremental rises were seen in each of the subsequent two years, with incidence reaching 
33 cases per 100,000 in England and Wales. Against a historical time series, this places 2016 as the 
highest scarlet fever year since 1967. Elevated incidence was seen across the country and whilst 
incidence varied, no discernible geographical gradient was evident. Outbreaks in schools and 
nurseries were common. A rise in hospital admission for scarlet fever was seen with 1 in 40 patients 
admitted for management of the condition or potential complications. Whole genome sequencing of 
clinical isolates identified no novel lineage or associated genetic element with a range of emm types 
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identified. Comparison with historical UK data showed that the magnitude of the recent upsurge in 
scarlet fever was exceptional, suggesting the current phenomenon is not explained by the usual 
cyclical patterns  in disease incidence. 
 
Implications of all the available evidence  
England is the first western hemisphere country to describe an upsurge in scarlet fever incidence 
following reports in several countries in the Far East. Microbial explanations have been largely 
excluded suggesting other forces are affecting our population’s susceptibility to this infection or its 
capacity to spread. Whilst most cases of scarlet fever are not severe, the rate of hospitalisation during 
this upsurge is relatively high and the impact substantial, in particular in the management of 
outbreaks. As such, uncovering the drivers behind this rise remains a priority. 
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INTRODUCTION 
The precipitous decline in many life-threatening infectious diseases during the course of the last 
century is well described but remains poorly understood. Improved living standards, in particular 
decreased crowding and improved hygiene and nutrition, and in due course immunisation and 
development of effective treatments are generally assumed to underpin this trend. Other explanations, 
however, including an evolutionary drift favouring the proliferation of less pathogenic strains may 
have also played a role. Scarlet fever, a toxin-mediated childhood exanthem resulting from 
Streptococcus pyogenes (group A Streptococcus) infection, is a case in point. A once common cause 
of childhood death, both its incidence and severity decreased dramatically during the 1800s and into 
the twentieth century, long before the widespread use of antibiotics.
1-4
 The commonplace suffering 
caused by scarlet fever and the measures taken to control its spread, including enforced removal of 
children to ‘fever hospitals’, have become a distant memory. Nonetheless, a revision of the legislation 
on statutory notification of infectious diseases in England and Wales in 2010 retained scarlet fever in 
its schedule in recognition of the importance of controlling outbreaks in schools and nurseries and the 
correlation between periodic increases in incidence of scarlet fever and severe infections caused by S. 
pyogenes.
5
 Both clinical manifestations share the same seasonal pattern with autumnal depression of 
incidence rising through the winter towards peak elevation in spring.
4,5
  
 
Within this context of overall diminishing incidence of scarlet fever, a sudden rise was noted during 
2014, with early indications suggesting a doubling in case numbers across England, Wales and 
Northern Ireland.
6
 Public health authorities from across the UK joined forces to co-ordinate measures 
to investigate the rise and control the spread of infection. Results from initial investigations 
undertaken in England are presented here.  
 
 
METHODS 
 
Case definitions and data sources 
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Scarlet fever cases were identified through multiple national surveillance systems. In accordance with 
statutory requirements suspected cases of scarlet fever are notified by clinicians to Public Health 
England (PHE) on the basis of signs and symptoms consistent with this condition, with or without 
laboratory confirmation of group A streptococcal (GAS) infection. Scarlet fever cases and outbreaks, 
defined as two or more cases within a 10 day period with an epidemiological link (e.g. same school 
class or year group), were notified directly to local PHE Health Protection Teams (HPTs).
7
 Historical 
time series of scarlet fever notifications were supplied by the Office for National Statistics (1912 to 
1997) to PHE’s predecessor organisation (Public Health Laboratory Service) when it assumed 
responsibility for the collection of notifiable diseases. Data on rates of disease in 1911 were obtained 
from a Medical Research Council epidemiological report.
8
 Annual counts (calendar year) for England 
and Wales combined were available from 1912 to 1982 and case level data thereafter.  
 
Cases were also identified via the PHE syndromic surveillance system.
9
 This sentinel network of 
primary care (general practitioner; GP) providers covering 5·5 million population was used to identify 
in-hours scarlet fever consultations on the basis of clinical Read codes (Clinical Terms Version 3, 
CTV3, Read codes: 65V7.; A34..; A341.; A34z.; Y9313; Y9314).
10
 All notifications of scarlet fever 
were submitted to the NHS Demographic Batch tracing Service to complete/confirm NHS numbers 
(unique patient identifier) and identify any deaths for further investigation through local HPTs. 
Hospital Episode Statistics
© 
(NHS Digital) were analysed to identify admissions to NHS hospitals and 
independent sector NHS treatment facilities in England for scarlet fever (International Statistical 
Classification of Diseases and Related Health Problems 10
th
 Revision, ICD-10 discharge diagnosis 
code A38). 
 
Microbiological characterisation of throat isolates from patients with scarlet fever submitted by 
microbiology laboratories as part of a sentinel sampling scheme were evaluated using emm gene 
sequencing. Further details on the sampling framework are provided elsewhere.
11
 In addition, data 
from laboratory notifications of invasive (iGAS) disease from across England, defined as GAS 
cultured from normally sterile sites, were extracted for analysis. 
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Data analysis 
All trend analyses of scarlet fever notifications were based on the date of notification with annual 
trends assessed according to calendar years or the GAS season, defined as running from week 37 
(using ISO calendar week numbering
12
) to week 36, equivalent to the second week in September 
through to the first week of the following September. Scarlet fever notifications were linked using 
NHS number to hospital admissions in the 7 days before and 30 days after onset of scarlet fever (or 
notification date if missing). Clinical assessment of ICD-10 diagnostic codes was undertaken to 
identify admissions related to the management of scarlet fever or potential complications including 
post-streptococcal sequelae.  
 
An independent assessment of scarlet fever incidence was undertaken using primary care 
consultations for scarlet fever. Comparison of scarlet fever GP consultation rates from regions 
covered by the primary care network were extrapolated to the whole of England to estimate the total 
number of cases seen by GPs. Confidence intervals around incidence rates were calculated assuming a 
Poisson distribution. 
 
Wavelet decomposition was undertaken in R using the WaveletCo package to investigate periodicity 
over the study period,
13
 along with descriptive analyses. Wavelet analysis undertakes a local time 
series decomposition of the signal (number of cases) and estimates how spectral characteristics 
change as a function of time.
14
  
 
The spatial density of scarlet fever rates were mapped using ESRI’s ArcGIS Desktop software using 
the Spatial Analyst extensions and the Kernel Density function to identify geographical ‘hotspots’. 
The rate of infection per 1000 population was calculated by geocoding the case postcodes and 
mapping them to 5km
2
 hexagonal grids and deriving population per grid cell using the National 
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Population Database Residential Population dataset. The centroid (X,Y) of each grid cell was then 
used to calculate a Kernel Density surface weighted by the infection rates for England. All other 
statistical analyses were undertaken in STATA statistical software (StataCorp. 2015. Stata Statistical 
Software: Release 13.1. College Station, TX, USA: Stata Corporation). 
 
Role of the funding source 
This study was funded by PHE, which received no external funding for the analysis. The 
corresponding author had full access to all the data in the study and had final responsibility for the 
decision to submit for publication. 
 
RESULTS  
Changes in disease incidence 
Subsequent to the marked declines in incidence of scarlet fever and associated deaths during the 
course of the 1900s, statutory notifications for England and Wales remained between 3·1 and 8·2 per 
100,000 population from 1999 to 2013, equating to 1,600 to 4,700 cases per calendar year (Figure 1). 
During February 2014, a steep increase in seasonal scarlet fever activity was observed, peaking in 
week 15 when 1,075 cases were notified (England only, Figure 2). Over the course of 2014, 15,637 
scarlet fever notifications were made, a rate of 27·2 per 100,000, a three-fold increase (RR=3·34; 95% 
CI 3·23-3·45) compared to 2013 (4,643 cases; 8·2/100,000). The seasonal pattern according to the 
relative distribution of cases across the year was similar during 2013/14 as for previous years. The 
subsequent seasons saw a return of elevated activity, with 17,696 notifications made in 2015 
(30·6/100,000) and 19,206 in 2016 (33·2/100,000), the highest rate since 1967 (Appendix, page 4). 
 
Analysis of data from the sentinel primary care network estimated a total of 26,500 (95% CI 19,500-
33,500) GP consultations for scarlet fever in England in 2014, an estimated two-fold elevation 
(RR=1·99; 1·95-2·03) compared to 2013 (13,200 consultations, 7,800-18,600).  
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Characteristics and distribution of cases 
Of the scarlet fever cases notified in 2014 in England, 50% (7,157/14,385) were male. The majority of 
cases (87%; 12,493/14,334) were in individuals less than 10 years old although notifications were 
received for individuals ranging in age from 0-90y (Figure 3). Population rates in male and female 
children aged <10y were 185·7 and 186·7 per 100,000 respectively in 2014 (Appendix, page 1). 
Disease incidence in adults differed between the sexes (Figure 3) with rates in females double those in 
males for 15-44 year olds (RR=1·95; 95% CI 1·70-2·24) and 45-64y olds (RR=2·52; 1·74-3·65). 
 
All parts of England experienced marked increases in the number and rate of scarlet fever notification 
in 2014 compared to 2013 (Appendix, page 2). Whilst rates of notification varied across the country 
(Figure 4), no clear geographical pattern was evident, with highest incidence densities seen in two 
discontiguous areas, Cumbria and Leicestershire. All regions saw incremental increases in rates 
between 2014 and 2016 with the exception of the East Midlands and Yorkshire & Humber, the two 
regions with the highest recorded rates in 2015 (44·1 and  49·3 per 100,000 population respectively; 
Appendix, page 2).  
 
Clinical complications  
The rise in scarlet fever incidence in 2014 was accompanied by an increase in hospitalisations for 
scarlet fever, evident from March onwards (Figure 5). The highest numbers of admissions (315) were 
seen in March 2016, more than triple the number in March 2013 (103). A total of 1,102, 1,190 and 
1,385 patients were admitted during 2014, 2015 and 2016 respectively compared to 703 in 2013; these 
equate to increases rising from 57% in 2014 to 97% in 2016 compared to 2013. The length of stay for 
patients admitted over this time period was similar (Kruskal-Wallis χ2(2df)=2·32, p=0·31), with 45% of 
admissions involving a stay of 1 or more nights in 2013 (IQR 0-1 day, range 0-16 days) and in 2014 
(IQR 0-1 day, 0-86 days) and 43% in 2015 (IQR 0-1 day, 0-23 days). 
 
Of the 14,396 scarlet fever cases notified in 2014, 4·6% (656) were identified through record linkage 
as having been admitted to hospital in the 30 days subsequent to onset (Table 1), a slightly lower 
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proportion than identified in 2013 (5·3%; 237/4,436; χ2(1df)=4·64; p=0·03). Of the 2014 admissions, 
the majority were emergency admissions (88%; 579/656) including those made through urgent GP or 
consultant clinic referral. A total of 369 of the 656 admitted patients (2·6% of all cases and 56·3% of 
admissions) had clinical codes indicating admission for management of scarlet fever, streptococcal 
infection or potential complications of scarlet fever. Of these admissions, scarlet fever was the most 
common presentation recorded (60%; 221) along with tonsillitis/pharyngitis (35%; 128). Potential 
complications were identified in 52 patients in 2014 (0·36% of all cases), 62% of which were 
admitted within 7 days of scarlet fever onset and 73% within 2 weeks. These included peritonsillar 
abscess (4), pneumonia (2), mastoiditis (1), cellulitis (6) and septic arthritis (1). Of particular concern 
were three admissions for sepsis, one of which indicated postpartum (puerperal) infection, and two 
patients with acute disseminated encephalitis. No significant differences were identified however in 
the proportion of admitted cases with any given complication compared to the previous year (Table 
1). No deaths attributed to scarlet fever were identified during 2014. 
 
 
Outbreaks of scarlet fever 
A total of 221 outbreaks of scarlet fever were recorded by local HPTs in 2014 with an increased 
number logged subsequent to the issuing of public health guidelines to assist local teams in consistent 
management and recording of outbreaks in April 2014 (Appendix, page 5). Further increases were 
noted in 2015 (471 outbreaks) and 2016 (620 outbreaks). The frequency of outbreaks followed the 
seasonal pattern of scarlet fever incidence with highest numbers recorded in March, comprising 44% 
(208) of all outbreaks in 2015 and 51% (318) in 2016. Of the 1,070 (98%) outbreaks in 2015-2016 for 
which details of the setting were available, 67% (719) were in schools and 31% (336) in nurseries. 
Very small numbers of outbreaks were logged in other settings, namely: households (4 outbreaks), 
care homes (2), college/university (2), other settings not further specified (4), and one each in a 
traveller community, workplace and custodial institution. 
 
Concurrent invasive GAS infection 
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Notifications of laboratory-confirmed invasive GAS (iGAS) infection during the heightened scarlet 
fever seasons (2013/14 to 2015/16) followed the same seasonal rise as scarlet fever. Weekly incidence 
remained in line with the previous season (Appendix, page 6) for the first two upsurge seasons with a 
total of 1,533 cases notified in 2012/13, 1,227 in 2013/14 and 1,627 in 2014/15. In 2015/16, an 
elevation in iGAS infection incidence was noted, with 2,049 cases notified during this season. 
 
Microbiological characteristics of circulating strains 
Assessment of 303 throat isolates collected across England during 2014 from patients with scarlet 
fever as part of their clinical care identified a genetically diverse population with a total of 16 
different emm types represented (Appendix, page 7). emm3 was most common (43%) type identified 
followed by emm12 (15%) and emm1 (11%).   
 
Longitudinal cyclical patterns 
Analysis of longitudinal trends in the incidence of scarlet fever notifications from 1911 onwards and 
deaths attributed to scarlet fever from 1901 (Figure 1) showed marked periodicity in incidence over 
time. Population rates of scarlet fever notifications prior to the current upsurge (1911-2011) peaked at 
a median of every 4 years (IQR 3·25-5·00y; Appendix, pages 8) with magnitude of increase between 
the lowest and highest point within each cycle averaging at a 41% increase (from RR=1·01 to 2·48). 
In contrast, a seven-fold increase was seen between 2011, the lowest incidence point in the cycle 
before the current upsurge, and 2016 (RR=6·85; 6·58–7·14). Assessment of scarlet fever mortality 
rates up to 1959, after which exceptionally few deaths were recorded, showed a similar cyclical 
pattern with a median 4 year interval between epidemic years (IQR 3-5y). Analysis of the periodicity 
of cases using wavelet analysis of annual counts of scarlet fever notification from 1912 to 2014 
identified significant 3-4 and 8 year cycling patterns (Appendix, page 9). This cycling gradually 
diminished from the 1940s until cases were too infrequent for significant cycling to be detected after 
the 1960s (Appendix, page 4).  
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DISCUSSION 
We describe an unexplained and ongoing resurgence of scarlet fever, which reached the highest levels 
of disease in 50 years with notifications made for 1 in 500 children under 10 years of age in 2014. The 
retention of scarlet fever in the schedule of notifiable diseases since 1899 has provided the 
epidemiological intelligence to detect this resurgence. No other European country has reported such a 
sudden rise, with a recent longitudinal assessment from Poland concluding that no similar explosive 
increases have been seen there.
15
 A number of countries in the Far East have reported an escalation of 
scarlet fever incidence, including Vietnam, South Korea, Hong Kong, and mainland China between 
2009 and 2015, with peak incidence rates broadly similar to ours around 24-30 cases per 100,000 
population.
4,16-18
 Whilst there is no clear connection between the situation in the UK and the Far East, 
a link cannot be wholly excluded without further understanding of the drivers behind these changes. 
 
Epidemiological analysis indicates no change in seasonal pattern or demographic features of cases 
during the current upsurge. Whilst children under the age of 10 years constitute the majority of cases, 
we note the wide age range and the slight excess numbers of young adult women diagnosed with 
scarlet fever, possibly reflecting a gender ratio in caring responsibilities for ailing (and infectious) 
children. Given the potentially severe nature of other manifestations of S. pyogenes infection and 
research which suggests that the same strains are responsible for non-invasive and invasive disease
19
, 
ensuring patients or parents are informed of measures to minimise onward transmission, particularly 
to vulnerable individuals such as those with chickenpox or in late term pregnancy, remains important.  
 
 
Investigations into the possible causes of the scarlet fever upsurge have to date focused on the 
potential expansion of a single clonal lineage or genetic elements within S. pyogenes to which there is 
consequently little or no population immunity. A sample of isolates from throat swabs taken across 
the country was collected and, whilst not entirely geographically representative, strains were 
submitted from most areas of England.
11
 Typing of the emm gene identified a diverse range of strain 
types although a dominance of emm3 was noted. Further analysis by whole genome sequencing did 
14 
 
not identify any common genetic element and comparison with historical strain collections identified 
that these were not newly emergent strains but represented established lineages within our 
population.
11
 As throat swabs are not routinely taken to confirm diagnosis, we expect some potential 
bias towards more intractable or severe infections amongst this collection,  although more systematic 
sampling from London also found a diverse range of strains.
20
 Of note, the particular (emm12) lineage 
isolated from a number of patients during the surge in scarlet fever in Hong Kong was absent from the 
isolates collected in the UK. Interestingly, phage with sequence homology to a phage detected in 
Hong Kong (HKU360.ssa) was found in emm12 strains in the UK, albeit in a minority of 
isolates.
11,21,22
 Further research is needed to explore the movement of mobile genetic elements 
between bacterial lineages and the influence of such elements on disease manifestation at a population 
level. Nonetheless, in the absence of clearly defined microbial characteristics that can explain the 
current epidemic, the hunt for further explanations for the rise in scarlet fever goes on.  
 
Other potential hypotheses include a return to a natural cyclical pattern of disease. This pattern was 
evident up until the 1940s and declined to the 1960s, in tandem with the widespread introduction of 
antibiotics. The recent upsurge in cases could represent a return to epidemic cycles, although our 
analysis suggests that the seven-fold increase between 2011 and 2016, the lowest and highest points in 
the current ‘cycle’, is of greater magnitude than any epidemic increases in previous years. Some of the 
recent increase may have been driven by increased completeness of reporting following the 
widespread media coverage. Despite there being a statutory obligation for medical practitioners to 
notify all patients with infectious diseases listed within the notification schedule,
23
 failure to notify 
does occur and as such, these data are treated as representing a signal to detect changes in incidence 
rather than an accurate estimate of total burden.
24
 This was confirmed by comparison of primary care 
data which suggested that notifications represent around half of all cases seen in England. Primary 
care data, however, also provided independent validation of the increase with a 2 to 3-fold elevation 
in incidence between 2013 and 2014,
25
 in line with that seen for notifications and hospital admissions. 
As such, we conclude that the current upsurge is both real and truly falls beyond that previously 
15 
 
documented suggesting an exceptional cause and not simply reflecting a natural cycle. Further 
understanding of the drivers behind the rise is essential to guide future prevention strategies. 
 
Outbreaks of scarlet fever had a considerable impact on schools and nurseries during this period. To 
assist local teams in managing these outbreaks, new guidance was developed including triggers for 
stepping up infection control measures in response to outbreaks with a prolonged duration or with 
severe outcomes.
7
 Ensuring the public and frontline healthcare professionals were aware of the 
increase in scarlet fever was achieved through sequential press releases with consistent messaging on 
the need for possible cases to be assessed by GPs and the importance of antibiotic treatment as a 
means to reduce risk of complications and onward transmission.
26,27
 
 
In recognition of the historical correlation between invasive and non-invasive disease, close 
monitoring of invasive GAS disease was undertaken during the scarlet fever upsurge.
5
 No rise in 
invasive disease was seen during 2014 or 2015 although a modest elevation was seen during 2016,
28
 
which is currently subject to further investigation. Where a clear burden was seen is in hospital 
admission of scarlet fever cases, either for management of their condition or for potential 
complications. Our comparison of pre and post upsurge admissions suggests no increased likelihood 
of hospitalisation, with around 1 in 40 cases in both years being admitted for management of the 
condition or recognised complications. Given the increase in absolute number of cases, however, a 
significant clinical and economic impact of hospital admission was documented during the current 
upsurge. Whilst most admissions were discharged within the same day and most commonly involved 
acute upper respiratory tract presentations, including otitis media, more severe complications were 
identified in a small number of patients, including two admissions with encephalitis and three with 
sepsis in 2014. Although we have no information on prior treatment during the current upsurge, early 
diagnosis and treatment may be life-saving for complications such as sepsis and this reinforces the 
importance of ensuring patients and GPs are aware of these potentially serious but uncommon 
complications. 
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FIGURE LEGENDS 
Figure 1 Annual rate of scarlet fever notifications and deaths in England and Wales, 1901 – 2016 
Rate of scarlet fever notifications and deaths per 100,000 population by calendar year. 
 
Figure 2 Weekly number of scarlet fever notifications by season, England 
Weekly number of notified cases of scarlet fever by season, defined as spanning from the second 
week in September (week 37)  through to the following first week of September (week 36). Data are 
shown for consecutive seasons from 2012/13 to 2015/16 along with average counts for each of the 
three preceding decennia.  
* mean number of weekly notifications 
 
Figure 3 Age distribution of scarlet fever notifications, England 2014 
Sex-specific distribution of the scarlet fever notifications by age of patient in years. Inset provides a 
magnified view of the age distribution in older children and adults depicting a divergence in numbers 
of cases in women and men from 15y to 50y.  
 
Figure 4 Geographical distribution of scarlet fever notification rates in England, 2014  
Kernel density surface of scarlet fever notifications per 1000 population based on hexagonal 5km
2
 
grid and 21·8 km kernel radius. Depth of colour denotes density from overlapping surfaces indicating 
‘hotspots’ of scarlet fever activity. 
 
Figure 5 Number of patients admitted to NHS hospitals in England for management of scarlet 
fever by month of admission 
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Table 1 Frequency and clinical characteristics of hospital admissions within 30 days of scarlet 
fever onset in notified cases, England 2013 - 2014 
 2013 2014 
 
No. (%) No. (%) 
Scarlet fever notifications   
  
Total number cases notified 4,436 (100%) 14,396 (100%) 
     
Hospital admissions in notified cases   
  
All admissions within 30d scarlet fever onset 237 (5·3%) 656 (4·6%) 
Emergency admissions 214 (4·8%) 579 (4·0%) 
Elective admission 20 (0·5%) 65 (0·5%) 
Other 3 (0·1%) 12 (0·1%) 
Admissions for scarlet fever management or complications 137 (3·1%) 369 (2·6%) 
Scarlet fever 83 (1·9%) 221 (1·5%) 
Tonsillitis/pharyngitis 48 (1·1%) 128 (0·9%) 
Acute upper respiratory tract infection 8 (0·2%) 30 (0·2%) 
     
Potential complications of scarlet fever 19 (0·4%) 52 (0·4%) 
Otitis media 6 (0·1%) 11 (0·1%) 
Peritonsillar abscess 0 (0·0%) 4 (0·0%) 
Pneumonia 0 (0·0%) 2 (0·0%) 
Mastoiditis 0 (0·0%) 1 (0·0%) 
Cellulitis 1 (0·0%) 6 (0·0%) 
Septic arthritis 1 (0·0%) 1 (0·0%) 
Sepsis 2 (0·0%) 3 (0·0%) 
Puerperal sepsis  0 (0·0%) 1 (0·0%) 
Acute disseminated encephalitis 0 (0·0%) 2 (0·0%) 
Streptococcal toxic shock like syndrome 1 (0·0%) 0 (0·0%) 
Febrile convulsions 3 (0·1%) 8 (0·1%) 
Post streptococcal sequelae* 1 (0·0%) 0 (0·0%) 
 
* acute rheumatic fever, reactive arthritis, acute glomerulonephritis, Sydenham’s chorea 
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SUPPLEMENTARY APPENDIX 
 
Resurgence of scarlet fever in England, 2014-2016: population-based surveillance  
Theresa Lamagni,
 
Rebecca Guy, Meera Chand, Katherine L Henderson, Victoria Chalker, James 
Lewis, Vanessa Saliba, Alex J Elliot, Gillian E Smith, Stephen Rushton, Elizabeth A Sheridan, Mary 
Ramsay, Alan P Johnson 
 
Supplementary Table 1 Age and sex-specific population rates (per 100,000 population) of scarlet fever 
notifications in 2014, England 
 female male   
age No. 
cases rate (95% CI) 
No. 
cases rate (95% CI) 
rate 
ratio p 
<10y 6107 186·73 (182·08 191·48) 6375 185·70 (181·17 190·32) 1·01 0·76 
10 - 14y 371 25·56 (23·02 28·30) 393 25·83 (23·34 28·51) 0·99 0·88 
15 - 44y 598 5·62 (5·18 6·09) 309 2·88 (2·57 3·22) 1·95 0·00 
45 - 64y 101 1·45 (1·18 1·76) 39 0·58 (0·41 0·79) 2·52 0·00 
65y+ 20 0·38 (0·23 0·59) 10 0·23 (0·11 0·43) 1·65 0·20 
all ages 7197 26·13 (25·53 26·74) 7126 26·62 (26·00 27·24) 0·98 0·27 
 
 
  
Necessary additional data
Click here to download Necessary additional data: sf paper (supplementary).pdf
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Supplementary Table 2 Geographical distribution of scarlet fever notifications by year, England  
 
 
 No. cases (rate per 100, 000 population) 
 2013 2014 2015 2016 
East of England 363 (6·10) 907 (15·07) 1319 (21·71) 1729 (36·97) 
East Midlands 413 (8·98) 2218 (47·83) 2064 (44·13) 1930 (22·25) 
London 483 (5·74) 1316 (15·41) 1644 (18·95) 1065 (40·58) 
North East 362 (13·87) 923 (35·25) 841 (32·04) 2724 (37·97) 
North West 741 (10·43) 2211 (31·00) 2272 (31·66) 3083 (34·45) 
South East 721 (8·20) 2386 (26·89) 2873 (32·11) 1706 (31·18) 
South West 483 (8·98) 1553 (28·64) 1541 (28·17) 1673 (29·09) 
West Midlands 240 (4·23) 1335 (23·37) 1336 (23·22) 2166 (40·18) 
Yorkshire & Humber 630 (11·80) 1496 (27·91) 2657 (49·28) 17780 (32·45) 
England 4436 (8·24) 14396 (26·50) 16545 (30·20) 1729 (36·97) 
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SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1 Annual rate of scarlet fever notifications in England and Wales, 1960 – 
2016  
Supplementary Figure 2 Number of clusters and outbreaks of scarlet fever recorded, England 
Supplementary Figure 3 Weekly number of invasive GAS infections notified by season, England 
Supplementary Figure 4 emm type distribution of scarlet fever throat isolates (n=303), England 
2014 
Supplementary Figure 5 Distribution of intervals between epidemic years of scarlet fever, England and 
Wales 
Supplementary Figure 6 Wavelet analysis of annual counts of scarlet fever notifications, England 1901-
2014 
Heatmap showing the extent of periodicity as estimated from a wavelet analysis of annual counts of scarlet fever 
notifications in England 1901-2014. Red areas denote significant cyclicity at periods represented on the y axis of 
the plot. The white dotted lines represent the boundaries within which there are sufficient data for the prediction 
to be made over that period of cycling. 
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Summary 
Background After decades of decreasing scarlet fever incidence, a dramatic increase was seen in 
England beginning in 2014. Investigations were launched to assess clinical and epidemiological 
patterns and identify potential causes. 
Methods Statutory scarlet fever notifications from 1911 onwards (England and Wales) were analysed 
to identify periods of sudden escalation. Characteristics of cases and outbreaks in England including 
frequency of complications and hospitalisations were assessed and compared to the pre-upsurge 
period. Isolates from throat swabs were collected and subjected to emm typing. 
Findings Population rates of scarlet fever increased three-fold between 2013 and 2014 from 8·2 to 
27·2 per 100,000 (RR=3·34; 95% CI 3·23-3·45); further increases in 2015 (30·6) and 2016 (33·2) 
reached the highest number (19,206 cases) and rate since 1967. Median age of cases in 2014 was 4y 
(range 0 – 90y) with rates of 186/100,000 in children under 10ys. All parts of England saw an 
elevation in incidence with 620 outbreaks reported in 2016. Scarlet fever hospital admissions 
increased by 97% between 2013 and 2016; 1 in 40 cases were admitted for management of the 
condition or potential complications. Analysis of strains (n=303) identified a diversitye range of emm 
types with 430% emm3, 15% emm12, 11% emm1, and 9% emm4. Longitudinal analysis identified 4-
yearly periodicity in incidence but of consistently this current escalation was of unprecedented lower 
magnitude than the current escalation. 
Interpretation England is experiencing an unprecedented rise in scarlet fever with the highest 
incidence for nearly 50 years. Reasons for this escalation are unclear and identifying these remains a 
public health priority. 
Funding This investigation was funded by Public Health England. 
 
KEYWORDS: Scarlet fever; Streptococcus pyogenes; Streptococcal infections/ Epidemiology; 
Streptococcal infections/ Prevention & Control; Population surveillance; Epidemics; England. 
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Research in context 
Evidence before this study  
A once common cause of childhood death, incidence and severity of scarlet fever dropped 
dramatically over the course of the nineteenth and twentieth centuries. The reasons for the decline, 
predating the advent of effective treatments, remain unexplained. Historical epidemiological patterns 
described in Europe and North America were are similar to those seen in modern times with highest 
incidence rates in children but with adults also susceptible to disease. Periodicity in disease incidence 
was well described with epidemic years occurring every 4-6 years.  
 
Subsequent to a prolonged period of low incidence, a dramatic escalation in scarlet fever incidence 
was seen in England during the spring of 2014, triggering a number of investigations to assess the 
impact and identify potential drivers. We searched PubMed for studies published between January 
2000 and July 2017, with the keywords “scarlet fever” and either “epidemiology” or “surveillance” to 
identify data from other countries describing recent trends. We also searched ProMED for posts 
mentioning “scarlet fever” without date restriction. This identified, sequential reports from Vietnam, 
South Korea, Hong Kong and mainland China describing sudden and widespread escalation of scarlet 
fever incidence were made from 2008 onwards. England is the first European country to note such a 
change.In England, a dramatic escalation in scarlet fever incidence was seen during the Spring of 
2014, the first European country to note such a change, triggering a number of investigations to assess 
the impact and identify potential drivers. 
 
 
Added value of this study  
Our study is the first to describe the impact of a modern-day resurgence in scarlet fever. We describe 
the sudden escalation in incidence in 2014 with notifications made for 1 in 500 children under 10 
years of age. Incremental rises were seen in each of the subsequent two years, with incidence reaching 
33 cases per 100,000 in England and Wales. Against a historical time series, this places 2016 as the 
highest scarlet fever year since 1967. Elevated incidence was seen across the country and whilst 
5 
 
incidence varied, no discernible geographical gradient was evident. Outbreaks in schools and 
nurseries were common. A rise in hospital admission for scarlet fever was seen with 1 in 40 
hospitalised patients admitted for management of the condition or potential complications. Whole 
genome sequencing of clinical isolates identified no novel lineage or associated genetic element with 
a range of emm types identified. Comparison with Analysis of historical UK data showed that 
epidemic escalation of the magnitude of the recent seen during our current upsurge in scarlet fever 
was exceptional, suggesting the current phenomenon is not explained by the usual cyclical patterns es 
in disease incidence. 
 
Implications of all the available evidence  
England is the first northern western hemisphere country to describe an upsurge in scarlet fever 
incidence following reports in several countries in the Far East. Whether other countries are currently 
experiencing a similar escalation is subject to uncertainty since many do not have specific 
surveillance systems to track this disease. Microbial explanations have been largely excluded 
suggesting other forces are affecting our population’s susceptibility to this infection or its capacity to 
spread. Whilst most cases of scarlet fever are not severe, the rate of hospitalisation during this upsurge 
is relatively high and the impact substantial, in particular in the management of outbreaks. As such, 
uncovering the drivers behind this rise remains a priority. 
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INTRODUCTION 
The precipitous decline in many life-threatening infectious diseases during the course of the last 
century is well described but remains poorly understood. Improved living standards, in particular 
decreased crowding and improved hygiene and nutrition, and in due course immunisation and 
development of effective treatments are generally assumed to underpin this trend. Other explanations, 
however, including an evolutionary drift favouring the proliferation of less pathogenic strains may 
have also played a role. Scarlet fever, a toxin-mediated childhood exanthem resulting from 
Streptococcus pyogenes (group A Streptococcus) infection, is a case in point. A once common cause 
of childhood death, both its incidence and severity decreased dramatically during the 1800s and into 
the twentieth century, long before the widespread use of antibiotics.
1-4
 The commonplace suffering 
caused by scarlet fever and the measures taken to control its spread, including enforced removal of 
children to ‘fever hospitals’, have become a distant memory. Nonetheless, a revision of the legislation 
on statutory notification of infectious diseases in England and Wales in 2010 retained scarlet fever in 
its schedule in recognition of the importance of controlling outbreaks in schools and nurseries and the 
correlation between periodic increases in incidence of scarlet fever and severe infections caused by S. 
pyogenes.
5
 Both clinical manifestations share the same seasonal pattern with autumnal depression of 
incidence rising through the winter towards peak elevation in spring.4,5  
 
Within this context of overall diminishing incidence of scarlet fever, a sudden rise was noted during 
2014, with early indications suggesting a doubling in case numbers across England, Wales and 
Northern Ireland.
6
 Public health authorities from across the UK joined forces to co-ordinate measures 
to investigate the rise and control the spread of infection. Results from initial investigations 
undertaken in England are presented here.  
 
 
METHODS 
 
Case definitions and data sources 
7 
 
Scarlet fever cases were identified through multiple national surveillance systems. In accordance with 
statutory requirements suspected cases of scarlet fever are notified by clinicians to Public Health 
England (PHE) on the basis of signs and symptoms consistent with this condition, with or without 
laboratory confirmation of group A streptococcal (GAS) infection. Scarlet fever cases and outbreaks, 
defined as two or more cases within a 10 day period with an epidemiological link (e.g. same school 
class or year group), were notified directly to local PHE Health Protection Teams (HPTs).
7
 Historical 
time series of scarlet fever notifications were supplied by the Office for National Statistics (1912 to 
1997) to PHE’s predecessor organisation (Public Health Laboratory Service) when it assumed 
responsibility for the collection of notifiable diseases. Data on rates of disease in 1911 were obtained 
from a Medical Research Council epidemiological report.
8
 Annual counts (calendar year) for England 
and Wales combined were available from 1912 to 1982 and case level data thereafter.  
 
Cases were also identified via the PHE syndromic surveillance system.
9
 This sentinel network of 
primary care (general practitioner; GP) providers covering 5·5 million population was used to identify 
in-hours scarlet fever consultations on the basis of clinical Read codes (Clinical Terms Version 3, 
CTV3, Read codes: 65V7.; A34..; A341.; A34z.; Y9313; Y9314).
10
 All notifications of scarlet fever 
were submitted to the NHS Demographic Batch tracing Service to complete/confirm NHS numbers 
(unique patient identifier) and identify any deaths for further investigation through local HPTs. 
Hospital Episode Statistics
© 
(NHS Digital) were analysed to identify admissions to NHS hospitals and 
independent sector NHS treatment facilities in England for scarlet fever (International Statistical 
Classification of Diseases and Related Health Problems 10
th
 Revision, ICD-10 discharge diagnosis 
code A38). 
 
Microbiological characterisation of throat isolates from patients with scarlet fever submitted by 
microbiology laboratories as part of a sentinel sampling scheme were evaluated using emm gene 
sequencing. Further details on the sampling framework are provided elsewhere.
11
 In addition, data 
from laboratory notifications of invasive (iGAS) disease from across England, defined as GAS 
cultured from normally sterile sites, were extracted for analysis. 
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Data analysis 
All trend analyses of scarlet fever notifications were based on the date of notification with annual 
trends assessed according to calendar years or the GAS season, defined as running from week 37 
(using ISO calendar week numbering
12
) to week 36, equivalent to the second week in September 
through to the first week of the following September. Scarlet fever notifications were linked using 
NHS number to hospital admissions in the 7 days before and 30 days after onset of scarlet fever (or 
notification date if missing). Clinical assessment of ICD-10 diagnostic codes was undertaken to 
identify admissions related to the management of scarlet fever or potential complications including 
post-streptococcal sequelae.  
 
An independent assessment of scarlet fever incidence was undertaken using primary care 
consultations for scarlet fever. Comparison of scarlet fever GP consultation rates from regions 
covered by the primary care network were extrapolated to the whole of England to estimate the total 
number of cases seen by GPs. Confidence intervals around incidence rates were calculated assuming a 
Poisson distribution. 
 
Wavelet decomposition was undertaken in R using the WaveletCo package used to investigate 
periodicity over the study period,
13
 along with descriptive analyses. Wavelet analysis undertakes a 
local time series decomposition of the signal (number of cases) and estimates how spectral 
characteristics change as a function of time.
14
  
 
The spatial density of scarlet fever rates wereas mapped using ESRI’s ArcGIS Desktop software using 
the Spatial Analyst extensions and the Kernel Density function to identify geographical ‘hotspots’. 
The rate of infection per 1000 population was calculated by geocoding the case postcodes and 
mapping them to 5km
2
 hexagonal grids and deriving population per grid cell using the National 
9 
 
Population Database Residential Population dataset. The centroid (X,Y) of each grid cell was then 
used to calculate a Kernel Density surface weighted by the infection rates for England. All other 
statistical analyses were undertaken in STATA statistical software (StataCorp. 2015. Stata Statistical 
Software: Release 13.1. College Station, TX, USA: Stata Corporation). 
 
Role of the funding source 
This study was funded by PHE, which received no external funding for the analysis. The 
corresponding author had full access to all the data in the study and had final responsibility for the 
decision to submit for publication. 
 
RESULTS  
Changes in disease incidence 
Subsequent to the marked declines in incidence of scarlet fever and associated deaths during the 
course of the 1900s, statutory notifications for England and Wales remained between 3·1 and 8·2 per 
100,000 population from 1999 to 2013, equating to 1,600 to 4,700 cases per calendar year (Figure 1). 
During February 2014, a steep acceleration increase in seasonal scarlet fever activity was observed, 
peaking in week 15 when 1,075 cases were notified (England only, Figure 2). Over the course of 
2014, 15,637 scarlet fever notifications were made, a rate of 27·2 per 100,000, a three-fold increase 
(RR=3·34; 95% CI 3·23-3·45) compared to 2013 (4,643 cases; 8·2/100,000). The seasonal pattern 
according to the relative distribution of cases across the year was similar during 2013/14 as for 
previous years. The subsequent seasons saw a return of elevated activity, with 17,696 notifications 
made in 2015 (30·6/100,000) and 19,206 in 2016 (33·2/100,000), the highest rate since 1967 
(Appendix, page 4Figure 1). 
 
Analysis of data from the sentinel primary care network estimated a total of 26,500 (95% CI 19,500-
33,500) GP consultations for scarlet fever in England in 2014, an estimated two-fold elevation 
(RR=1·99; 1·95-2·03) compared to 2013 (13,200 consultations, 7,800-18,600).  
10 
 
 
Characteristics and distribution of cases 
Of the scarlet fever cases notified in 2014 in England, 50% (7,157/14,385) were male. The majority of 
cases (87%; 12,493/14,334) were in individuals less than 10 years old although notifications were 
received forin individuals ranging in age from spanning the full age range (0-90y (; Figure 3). 
Population rates in male and female children aged <10y were 185·7 and 186·7 per 100,000 
respectively in 2014 (Suppl Table 1Appendix, page 1). Disease incidence in adults differed between 
the sexes A sex gradient was apparent in adults (Figure 3) with rates in females double those in males 
for 15-44 year olds (RR=1·95; 95% CI 1·70-2·24) and 45-64y olds (RR=2·52; 1·74-3·65). 
 
All parts of England experienced marked increases in the number and rate of scarlet fever notification 
in 2014 compared to 2013 (Appendix, page 2Suppl Table 2). Whilst rates of notification varied across 
the country (Figure 4), no clear geographical pattern was evident, with highest incidence densities 
seen in two discontiguous areas, in Cumbria and Leicestershire. All regions saw incremental increases 
in rates between 2014 and 2016 with the exception of the East Midlands and Yorkshire & Humber, 
the two regions with the highest recorded rates in 2015 (44·1 and  49·3 per 100,000 population 
respectively; Appendix, page 2Suppl Table 2).  
 
Clinical complications  
The rise in scarlet fever incidence in 2014 was accompanied by an increase in hospitalisations for 
scarlet fever, evident from March onwards (Figure 5). The highest numbers of admissions (315) were 
seen in March 2016, more than triple the number in March 2013 (103). A total of 1,102, 1,190 and 
1,385 patients were admitted during 2014, 2015 and 2016 respectively compared to 703 for in the 
previous year2013; these equate to increases rising from of 57% in 2014 to 97% in 2016 
respectivelycompared to 2013. The length of stay for patients admitted over this time period was 
similar (Kruskal-Wallis χ2(2df)=2·32, p=0·31), with 45% of admissions involving a stay of 1 or more 
nights in 2013 (IQR 0-1 day, range 0-16 days) and in 2014 (IQR 0-1 day, 0-86 days) and 43% in 2015 
(IQR 0-1 day, 0-23 days). 
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Of the 14,396 scarlet fever cases notified in 2014, 4·6% (656) were identified through record linkage 
as having been admitted to hospital in the 30 days subsequent to onset (Table 1), a slightly lower 
proportion than identified in 2013 (5·3%; 237/4,436; χ2(1df)=4·64; p=0·03). Of the 2014 admissions, 
the majority were emergency admissions (88%; 579/656) including those made through urgent GP or 
consultant clinic referral. A total of 369 of the 656 admitted patients (2·6% of all cases and 56·3% of 
admissions) had clinical codes indicating admission for management of scarlet fever, streptococcal 
infection or potential complications of scarlet fever. Of these admissions, scarlet fever was the most 
common presentation recorded (60%; 221) along with tonsillitis/pharyngitis (35%; 128). Potential 
complications were identified in 52 patients in 2014 (0·36% of all cases), 62% of which were 
admitted within 7 days of scarlet fever onset and 73% within 2 weeks. These included peritonsillar 
abscess (4), pneumonia (2), mastoiditis (1), cellulitis (6) and septic arthritis (1). Of particular concern 
were three admissions for sepsis, one of which indicated postpartum (puerperal) infection, and two 
patients with acute disseminated encephalitis. No significant differences were identified however in 
the proportion of admitted cases with any given complication compared to the previous year (Table 
1). No deaths attributed to scarlet fever were identified during 2014. 
 
 
Outbreaks of scarlet fever 
A total of 221 outbreaks and clusters of scarlet fever were recorded by local HPTs in 2014 with an 
increased number logged subsequent to the issuing of public health guidelines to assist local teams in 
consistent management and recording of outbreaks in April 2014 (Appendix, page 5Suppl Fig 1). 
Further increases were noted in 2015 (471 outbreaks) and 2016 (620 outbreaks). The frequency of 
outbreaks followed the seasonal pattern of scarlet fever incidence with highest numbers recorded in 
March, comprising 44% (208) of all outbreaks in 2015 and 51% (318) in 2016. Of the 1,070 (98%) 
outbreaks/clusters in 2015-2016 for which details of the setting were available, 67% (719) were in 
schools and 31% (336) in nurseries. Very small numbers of outbreaks were logged in other settings, 
12 
 
namely: households (4 outbreaks), care homes (2), college/university (2), other settings not further 
specified (4), and one each in a traveller community, workplace and custodial institution. 
 
Concurrent invasive GAS infection 
Notifications of laboratory-confirmed invasive GAS (iGAS) infection during the heightened scarlet 
fever seasons (2013/14 to 2015/16) followed the same seasonal rise as scarlet fever. Weekly incidence 
remained in line with the previous year season (Appendix, page 6Suppl Fig 2) for the first two 
upsurge years seasons with a total of 1,533 cases notified in 2012/13, 1,227 in 2013/14 and 1,627 in 
2014/15. In 2015/16, an elevation in iGAS infection incidence was noted, with 2,049 cases notified 
during this yearseason. 
 
Microbiological characteristics of circulating strains 
Assessment of 303 throat isolates collected across England during 2014 from patients with scarlet 
fever as part of their clinical care identified a genetically diverse population range of strain types with 
a total of 16 different emm types represented (Appendix, page 7Figure 6). emm3 was most common 
(43%) type identified followed by emm12 (15%) and emm1 (11%).   
 
Longitudinal cyclical patterns 
Analysis of longitudinal trends in the incidence of scarlet fever notifications from 1911 onwards and 
deaths attributed to scarlet fever from 1901 (Figure 1) showed marked periodicity in incidence over 
time. Population rates of scarlet fever notifications prior to the current upsurge (1911-2011) peaked at 
a median of every 4 years (IQR 3·25-5·00y; Appendix, pages 8Suppl Fig 3) with magnitude of 
increase between the lowest and highest point within each cycle averaging at a 41% increase (from 
RR=1·01 to 2·48). In contrast, a seven-fold increase was seen between 2011, the lowest incidence 
point in the cycle before the current upsurge, and 2016 (RR=6·85; 6·58–7·14). Assessment of scarlet 
fever mortality rates up to 1959, after which exceptionally few deaths were recorded, showed a 
similar cyclical pattern with a median 4 year interval between epidemic years (IQR 3-5y). Analysis of 
the periodicity of cases using wavelet analysis of annual counts of scarlet fever notification from 1912 
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to 2014 identified significant 3-4 and 8 year cycling patterns (Appendix, page 9Suppl Fig 4). This 
cycling gradually diminished from the 1940s until cases were too infrequent for significant cycling to 
be detected after the 1960s (Appendix, page 4).  
 
 
DISCUSSION 
We describe an unexplained and ongoing resurgence of scarlet fever, which reached the highest levels 
of disease in 50 years with notifications made for 1 in 500 children under 10 years of age in 2014. The 
retention of scarlet fever in the schedule of notifiable diseases since 1899 has provided the 
epidemiological intelligence to detect this resurgence. Whilst Nno other European country has 
reported such a sudden rise, with , their ability to do so may be hampered in some instances by a lack 
of consistent surveillance data. One exception is Poland wherea a recent longitudinal assessment from 
Poland concludinged that no similar explosive increases have been seen there.
15
 A number of 
countries in the Far East have reported an escalation of scarlet fever incidence, including Vietnam, 
South Korea, Hong Kong, and mainland China between 2009 and 2015, with peak incidence rates 
broadly similar to ours around 24-30 cases per 100,000 population.
4,16-18
 Whilst there is no obvious 
clear connection between the situation in the UK and the Far East, a link cannot be wholly excluded 
without further understanding of the drivers behind these changes. 
 
Epidemiological analysis indicates no change in seasonal pattern or demographic features of cases 
during the current upsurge. Whilst children under the age of 10 years constitute the majority of cases, 
we note the wide age range and the slight excess numbers of young adult women diagnosed with 
scarlet fever, possibly reflecting a gender ratio in caring responsibilities for ailing (and infectious) 
children. Given the potentially severe nature of other manifestations of S. pyogenes infection and 
research which suggests that the same strains are responsible for non-invasive and invasive disease
19
, 
ensuring patients or parents are informed of measures to minimise onward transmission, particularly 
to vulnerable individuals such as those with chickenpox or in late term pregnancy, remains important.  
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Investigations into the possible causes of the scarlet fever upsurge have to date focused on the 
potential expansion of a single clonal lineage or genetic elements within S. pyogenes to which there is 
consequently little or no population immunity. A sample of isolates from throat swabs taken across 
the country was collected and, whilst not entirely geographically representative, strains were 
submitted from most areas of England.
11
 Typing of the emm gene identified a diverse range of strain 
types although a slight dominance of emm3 was noted. Further analysis by whole genome sequencing 
did not identify any common genetic element and comparison with historical strain collections 
identified that these strains were not newly emergent  strains but represented established lineages 
within our population.
11
 As throat swabs are not routinely taken to confirm diagnosis, we expect some 
potential bias towards more intractable or severe infections amongst this collection,  although more 
systematic sampling from London also found a diverse range of strainsisolates.20 Of note, the 
particular (emm12) lineage isolated from a number of patients associated withduring the surge in 
scarlet fever in Hong Kong was absent from the isolates collected in the UK. Interestingly, phage with 
sequence homology to a phage detected in Hong Kong (HKU360.ssa) was found in emm12 strains in 
the UK, albeit in a minority of isolates.
11,21,22
 Further research is needed to explore the movement of 
mobile genetic elements between bacterial lineages and the influence of such elements on disease 
manifestation at a population level. Nonetheless, in the absence of clearly defined microbial 
characteristics that can explain the current epidemicWith no indication that microbial characteristics 
can explain the current epidemic, the hunt for further explanations for the rise in scarlet fever goes on.  
 
 
Other potential hypotheses include a return to a natural cyclical pattern of disease. This pattern was 
evident up until the 1940s and declined to the 1960s, in tandem with the widespread introduction of 
antibiotics. The recent upsurge in cases could represent a return to epidemic cycles, although our 
analysis suggests that the seven-fold increase between 2011 and 2016, the lowest and highest points in 
the current ‘cycle’, is of greater magnitude than any epidemic increases in previous years. Some of the 
recent increase, however,  may have been driven by increased completeness of reporting following the 
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widespread national and local media coverage of the rise in scarlet fever. Despite there being a 
statutory obligation for medical practitioners to notify all patients with infectious diseases listed 
within the notification schedule,
23
 failure to make such notifyication does occur and as such, these 
data are treated as representing a signal to detect changes in incidence rather than an accurate estimate 
of total burden.
24
 This was confirmed by comparison of primary care data which suggested that 
notifications only represent around half of all cases seen in England. The Pprimary care data, 
however, also provided independent validation of the increase with a 2 to 3-fold elevation in 
incidence between 2013 and 2014,
25
 in line with that seen in for notifications and the number of cases 
hospital admissionstted to hospital. As such, we conclude that the current upsurge is both real and 
truly falls beyond that previously documented suggesting an exceptional cause and not simply 
reflecting a natural cycle. Further understanding of the drivers behind the rise is essential to guide 
future prevention strategies. 
 
Outbreaks of scarlet fever had a considerable impact on schools and nurseries during this period. To 
assist local teams in managing these outbreaks, new guidance was developed including triggers for 
stepping up infection control measures in response to outbreaks with a prolonged duration or with 
severe outcomes.7 Ensuring the public and frontline healthcare professionals were aware of the 
increase in scarlet fever was achieved through sequential press releases with consistent messaging on 
the need for possible cases to be assessed by GPs and the importance of antibiotic treatment as a 
means to reduce risk of complications and onward transmission. As a previously uncommon 
condition, ensuring GPs and practice nurses were aware of the signs and symptoms and the need for 
antibiotic treatment, in contrast to concurrent messaging to reduce antibiotic prescribing, was 
particularly important in managing the incident.
26,27
 
 
In recognition of the historical correlation between invasive and non-invasive disease, close 
monitoring of invasive GAS disease was undertaken during the scarlet fever upsurge.
5
 No rise in 
invasive disease was seen during 2014 or 2015 although a modest Whilst incidence was elevationed 
was seen during 2016, this rise was relatively modest in scale and no proportionate rise in invasive 
16 
 
disease was seen during 2014-2015.
28
 which is currently subject to further investigation. Where a 
clear burden was seen is in hospital admission isations of scarlet fever cases, either for management of 
their condition or for potential complications. Our comparison of pre and post upsurge admissions 
suggests no increased likelihood of hospitalisation, with around 1 in 40 cases in both years being 
admitted for management of the condition or recognised complications. Given the increase in absolute 
number of cases, however, a significant clinical and economic impact of hospital admission was 
documented during the current upsurge. Whilst most admissions were discharged within the same day 
and most commonly involved acute upper respiratory tract presentations, including otitis media, were 
the most common reasons for admission noted, more severe complications were identified in a small 
number of patients, including two admissions with encephalitis and three with sepsis in 2014. 
Although we have no information on prior treatment during the current upsurge, early diagnosis and 
treatment may be life-saving for complications such as sepsis and this reinforces the importance of 
ensuring patients and GPs are aware of these potentially serious but uncommon complications. 
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FIGURE LEGENDS 
Figure 1 Annual rate of scarlet fever notifications and deaths in England and Wales, 1901 -– 
2016 
Rate of scarlet fever notifications and deaths per 100,000 population by calendar year. 
 
Figure 2 Weekly number of scarlet fever notifications by season, England 
Weekly number of notified cases of scarlet fever by season, defined as spanning from the second 
week in September (week 37)  through to the following first week of September (week 36). Data are 
shown for consecutive seasons from 2012/13 to 2015/16 along with average counts for each of the 
three preceding decennia.  
* mean number of weekly notifications 
 
Figure 3 Age distribution of scarlet fever notifications and associated hospital admissions, 
England 2014 
Sex-specific distribution of the scarlet fever notifications by age of patient in years. Inset provides a 
magnified view of the age distribution in older children and adults depicting a divergence in numbers 
of cases in women and men from 15y to 50y.  
 
Figure 4 Geographical distribution of scarlet fever notification rates in England, 2014  
Kernel density surface of scarlet fever notifications per 1000 population based on hexagonal 5km
2
 
grid and 21·8 km kernel radius. Depth of colour denotes density from overlapping surfaces indicating 
‘hotspots’ of scarlet fever activity. 
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Figure 5 Number of patients admitted to NHS hospitals in England for management of scarlet 
fever by month of admission  
Figure 6 emm type distribution of scarlet fever throat isolates (n=303), England 2014 
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Re: Resurgence of scarlet fever in England, 2014-2016 (THELANCETID-D-17-01016) 
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*Reply to Reviewers Comments
 2 
Editorial points: 
 
5- Be aware that the maximum number of non-text items (figures and tables)in the main article is six. 
You have seven non-text items at the moment, so you need to move at least one figure/table to the 
Appendix.  
 
RESPONSE: we have moved the emm type Figure (Fig 6) to the supplementary materials. 
 
6- The Appendix should be a single PDF file with page numbers. Please refer to any figure or table in 
the Appendix with its page number only ("Appendix, page ..."). 
 
RESPONSE: now amended as requested. 
 
9- Titles of all research articles should include a study descriptor: such as "a randomised placebo-
controlled phase 3 study", and "an observational cohort study", "a systematic review and meta-
analysis". Please ensure that you have included a descriptor in the title of your article. 
 
RESPONSE: amended to now include ‘ :population-surveillance’ at the end of the title. 
 
10- In the panel Research in Context - Evidence before this study - please indicate your search 
strategy up to the most recent date. This means that you need to indicate dates, sources and 
keywords used for such search. No citations or references are allowed. You can find an example in 
this published article (http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30321-
3/fulltext) 
 
RESPONSE: now included. 
 
Reviewers' comments: 
 
Reviewer #1: In this descriptive summary it appears that the authors have indeed demonstrated that  
England is experiencing a rise in scarlet fever with the highest incidence for nearly 50 years.. 
 
The tables and figures are well presented and their message is clear in the recent trends noted. The 
statistical and epidemiological treatment of the data are as one would expect in this context 
including the RR with confidence intervals as well as the limited non parametric comparisons.  
 
On page 11 the authors note that analysis of longitudinal trends in the incidence of scarlet fever 
notifications from 1911 onwards and deaths attributed to scarlet fever from 1901 (Fig 1) showed 
marked periodicity in incidence over time. With respect to notifications, this may be the case (i.e. 
marked periodicity) for the period 1911 to 1971. However, without some amplification of the plot 
beyond 1971 or a time series modeling strategy from 1971  onward, this is not that obvious on this 
particular figure. It may be a bit more obvious on the wavelet pattern, supplementary Figure 4. 
 
RESPONSE: It is indeed quite difficult to see any periodic rises in scarlet fever incidence from Figure 1 
beyond the 1960s due to the scale of the graph. Although the wavelet analysis indicates some weak 
cyclical patterns as described in the text, we’ve added an additional Figure to the Supplementary 
data (Supplementary Figure 1) to more clearly show the pattern of incidence since 1960. 
 
3 
The authors should check the labeling on the supplemental figures. In the text and on the legend they 
are listed as  Supplementary Figures 1 to 4. On the actual figures they are labeled Supplementary 
Figures 7 to 10. 
 
RESPONSE: thank you for pointing this out. Labels now corrected. 
 
Reviewer #2: I do not believe in hiding behind blind peer review and think that my opinion has less 
value if I am not willing to stand behind it.  Therefore, these are the comments of Dr. Stephen Beres. 
 
MAJOR concerns and comments 
 
I have no major concerns or comments, which is why I have recommended acceptance with minor 
revisions. 
 
MINOR concerns and comments 
 
These comments and concerns are intended to provide an outside perspective and feedback.  In my 
opinion they do not all require a point-by-point response.  Some of them are simply suggested 
rephrasing of what the authors have said with the intention of enhancing clarity. 
 
RESPONSE: thank you for these helpful suggestions. We’ve amended the text as noted below.  
 
Page 2, paragraph 2 - with rates of 186/100,000 in under 10s. 
 
Suggest - with rates of 186/100,000 in under 10 years of age.  Which is how it is expressed on page 3 
in paragraph 3. 
 
RESPONSE: abstract text amended. 
 
Page 6, paragraph 2 - CTV3 and ICD-10 are these acronyms, should they be defined? 
 
RESPONSE: acronyms now spelt out in full. 
 
Page 7, paragraph 1 - trends assessed according to calendar years or the GAS season, defined as 
running from week 37 (using ISO calendar week numbering12) to week 36. 
 
Suggest - As a courtesy to the reader who in general is probably much more familiar with a 
dd/mm/yyyy date format then with successive weeks of the calendar year (nobody when asked what 
their birthday is responds - it is the second day of the 19th week) I suggest expressing the "GAS 
season" additionally in terms such as from the 1st week of October to the last week of September.  It 
would also be helpful, if the GAS disease frequency is going to be expressed in terms of GAS "season", 
to have some basic description of how GAS disease/SF varies seasonally, that is for continental 
climates such as for the UK, in general the incidence of GAS infection is lowest during the warm 
summer months and into the early fall, increases with cooling temperatures during the latter months 
of the year, peaks during the cold early months of the year, and then decreases with warming 
temperatures during the spring. 
 
RESPONSE: we have expanded the Introduction to include a description of the seasonal pattern and 
also included a description to the Figure 2 legend to assist readers in translating the week numbers 
into calendar months. 
 
4 
Page 7, paragraph 3 - Wavelet decomposition was used to investigate periodicity …  Is it relevant to 
indicate what software/programs were used for the Wavelet analysis, as ArcGIS is sited for the 
geospatial analyses and STATA is listed for the statistical analyses? 
 
RESPONSE: software used, including specific analytical package (R WaveletCo package) now 
included. 
 
Page 8, RESULTS paragraph 1 - … equating to 1,600 to 4,700 cases per year (Figure 1).  
 
Suggest - … equating to 1,600 to 4,700 cases per calendar year (Figure 1).  
Since both "calendar year" and "GAS seasonal year" (wk 37-to-36) are used throughout the 
manuscript as time periods for assessing the incidence of GAS infection, and to my reading it is not 
always clear which is being used.  Moreover, as Figure 1 seems to have a title but no legend, what 
the year long period is, can not be clarified by reading the figure legend. 
 
RESPONSE: ‘calendar’ year has been inserted in the Results text and the Figure 1 legend expanded to 
clarify.  
 
Page 8, RESULTS paragraph 1 - … a steep acceleration in seasonal scarlet fever activity was observed, 
… 
 
Suggest - a steep increase in seasonal scarlet fever activity was observed, … 
Acceleration: increase in speed or velocity 
 
RESPONSE: text amended as suggested. 
 
Page 8, RESULTS paragraph 1 - Figure 2 seems to have a title but no legend. A legend to Figure 2 
would be an ideal location to describe GAS disease/SF seasonal incidence fluctuation in the UK. 
 
RESPONSE: legend now inserted clarifying the months which the week numbers correspond to.  
 
Page 8, last paragraph - The majority of cases (87%; 12,493/14,334) were less than 10 years old 
although notifications were received in individuals spanning the full age range (0-90y; Figure 3). 
 
Suggest - The majority of cases (87%; 12,493/14,334) were in individuals less than 10 years old 
although notifications were received for individuals that ranged in age from 0-90y (Figure 3).  The 
statement in the submission makes it sound like the "cases" are young instead of occurring in the 
young, and like the "full age range" in the UK is 0-to-90 years, that is that no one in the UK obtains an 
age greater than 90. 
 
RESPONSE: text now amended and reads as follows: “The majority of cases (87%; 12,493/14,334) 
were in individuals less than 10 years old although notifications were received for individuals ranging 
in age from 0-90y (Figure 3).” 
 
Page 8, last paragraph - A sex gradient was apparent in adults (Figure 3) with rates in females double 
those in males … 
 
Suggest - Disease incidence in adults was different between the sexes (Figure 3) with rates in females 
double those in males …  (Figure 3) … Nobody asks - What was the sex gradient at the party you were 
at last night?   
 
RESPONSE: text amended as suggested. 
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Additionally, since 50% of disease notifications were in males then this must require that there was 
another age group in which the rate was higher in the males than females - what age group was 
that? Or possibly there is some significant difference in the portion of the UK population that is male 
vs female.  The point in the graph where male cases seem to be higher than females is for the ~5 year 
olds, but the population rate in those less than 10 years old was higher for females than males - how 
are both of these possible unless there are substantially more males than females in the less than 10 
year old age group. 
 
RESPONSE: there were in fact more cases in males than females aged <10y, but as shown in the 
Supplementary table, the incidence rate is very similar between the two sexes owing to the 
substantial excess of male births to female in the UK (seen in most countries). So whilst the number 
cases is 4% higher in males <10y than females, the male population (<10y) is 5% bigger than the 
female. 
 
Page 8, last paragraph - Figure 3 seems to have a title but no legend.  I am not sure that I know 
exactly what is being graphed, is it notifications is it hospitalizations, is it the sum of the both, are 
notifications and hospitalizations separate or do some of the notifications go on to be 
hospitalizations.  The point of the inset graph is not made but would seem to be to illustrate the 
difference in the 15-to-44 year old age group. Is a similar inset needed to illustrate the apparent sex 
difference in the 0-to-10 age group? 
 
RESPONSE: the title and legend have been amended to clarify the data shown and to describe the 
inset. There’s no real sex difference in younger children as mentioned above so no special mention is 
given to this. 
 
Page 9, 1st paragraph - Whilst rates of notification varied across the country (Figure 4), no clear 
geographical pattern was evident, 
 
Question - Given that GAS is a human specific pathogen with no known non-human or environmental 
reservoir, I almost invariably observe a population density association with GAS infections, that is 
where more people live there are more cases of GAS infection. From the methods page 7 "deriving 
population per grid cell" I got the impression that population density was a parameter that was 
being assessed relative to geography.  Do the authors mean that there was no 
correlation/association between population density and the number of infections, that locations with 
low population density had the same rate of notifications as regions of high population density.  
Please clarify or elaborate on what questions/hypothesis were being asked about the epidemic with 
respect to geography. 
 
RESPONSE:  the geospatial analysis was simply to assess whether there were substantial variations in 
incidence across the country, taking into account the background population count in any given area 
(cell). As such, it was not to assess whether there was higher incidence according to population 
density per se, which would in fact be rather complex as it would need to factor in density of primary 
school-aged children and exploration of other influencing factors (such as scale of analysis, 
distribution of schools and nurseries). It was intended to simply describe the incidence across the 
country, in part to identify any patterns that could shed light on why the elevation was seen and to 
also assess which parts of the country were most affected.  We see this as part of the overall study 
objective, to describe the epidemiological changes as a means to investigate the possible reasons for 
the rise and to assess its impact. As such, we do not feel that further text is needed to clarify why 
this analysis has been undertaken.   
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Page 9, 2nd paragraph - … these equate to increases of 57% to 97% respectively. 
 
Questions - Increases relative to what, 2013? What and what respectively? - 2015 to 2014?, 2016 to 
2015?, minimum to maximum? This is unclear. 
 
RESPONSE: text has been amended to remove ambiguity. The elevations were all being compared to 
the baseline year of 2013. 
 
Page 10, 2nd paragraph - A total of 221 outbreaks and clusters of scarlet fever were recorded by 
local HPTs - outbreaks have been defined as 2 or more cases within a 10 day period with an 
epidemiological link, but what constitutes a cluster? Is a cluster a set of cases in a 10 day period 
without epidemiological links? Please define. 
 
RESPONSE: the text has been amended to just refer to outbreaks as we have no separate definition 
of a cluster for scarlet fever in our national guidelines (ref 7).  
 
Page 10, 3rd paragraph - Weekly incidence remained in line with the previous year (Suppl Fig 2) for 
the first two upsurge years with a total of 1,533 cases notified in 2012/13, 1,227 in 2013/14 and 
1,627 in 2014/15. 
 
Suggest - "year" here now seems to be being used to refer to "GAS seasons" not to calendar year - to 
avoid confusion suggest using "GAS disease/SF season" when you mean 2014-2015 and year when 
you mean Jan 1 2013 to Dec 31 2013. 
 
RESPONSE: ‘year’ changed to ‘season’ to clarify. 
 
Page 11, 1st paragraph - … identified a diverse range of strain types with a total of 16 different emm 
types represented (Figure 6). 
Suggest - … identified a genetically diverse population with a total of 16 different emm types 
represented (Figure 6). 
 
RESPONSE: amended as suggested. 
 
Page 11, 1st paragraph - emm3 was most common (43%) type identified… -- the 43% value is 
different then the 40% given on page 2 paragraph 2 
 
RESPONSE: thank you for spotting the inconsistency. Text now amended (43% correct).  
 
Page 11, 2nd paragraph - In all prior paragraphs Fig is spelled out as Figure, for self consistency 
suggest spelling it out here also. Moreover, the numbers of the supplemental figures provided in this 
paragraph (sup fig 3 an 4) and on page 3 of the supplement do not match the numbers actually on 
the supplemental figures (sup fig 7, 8, 9, 10). 
 
RESPONSE: ‘Fig’ now amended to ensure consistency. Supplementary Figs renumbered to ensure 
they match the legend numbering. 
 
Page 11, last paragraph - Whilst no other European country has reported such a sudden rise, their 
ability to do so may be hampered in some instances by a lack of consistent surveillance data.  
Caution - This is the second time the authors have implied that the reason that a similar epidemic of 
scarlet fever has not been reported for other countries of Europe is because they are potentially not 
7 
as good at surveillance as in England.  I do not think this is a good idea.  Do the authors really think 
that if scarlet fever infections had increased several fold in Finland, Norway, France, Sweden, etc.. 
that it would have gone unnoticed.  I suggest simply pointing out that a similar increase in scarlet 
fever in other countries of Europe has not been reported without speculating as to why or implying 
that others are in some way less competent. 
 
RESPONSE: it is certainly not our view that public health institutes in other countries are less 
‘competent’ than the UK but rather that some may lack the epidemiological data to identify such a 
change. We agree that there are many countries with excellent public health infrastructure who 
would be aware if they were experiencing the same phenomenon, but we still maintain that a similar 
phenomenon (perhaps to a lesser extent) could be happening in some countries without them being 
aware. As such, we have reworded this paragraph as suggested and also added ‘any’ to the Research 
in context paragraph to make clear that we’re not referring to all countries. 
 
Page 12, last paragraph - Typing of the emm gene identified a diverse range of strain types although 
a slight dominance of emm3 was noted. 
 
Comment - From page 11 emm3 was 43% and then emm12 was 15%, given that emm3 was nearly 3 
times more prevalent than the next most prevalent emm-type, I would not describe it as a "slight 
dominance".  Suggest simply stating that emm3 was 3 times as prevalent as the next most prevalent 
emm-type. 
 
RESPONSE:  ‘slight’ now removed from text. 
 
Page 13, 1st paragraph - Other potential hypotheses include a return to a natural cyclical pattern of 
disease. 
Comment - This to me really does not say anything. So let's go with the hypothesis and assume that 
what is going on is a return to the natural cycle - That only begs the exact same question as for the 
epidemic increase, which is why? what has changed in the bacteria, host, environment, or the 
interaction between these elements to account for the epidemic? 
 
RESPONSE: cyclical patterns in infectious diseases are well described but not entirely well 
understood. An accumulation of susceptible individuals with the addition of successive birth cohorts 
is a likely explanation but alternatives have been postulated. We think that it is beyond the scope of 
this paper to provide a detailed discussion around this. We have described historical epidemic cycles 
and simply state in this paragraph that the current pattern doesn’t fit with these cycles. 
 
Page 13, 1st paragraph - Some of the recent increase, however, may have been driven by increased 
completeness of reporting following the widespread national and local media coverage of the rise in 
scarlet fever. 
 
Comment and Opinion - I find this weak also.  Although I am willing to accept that increased 
awareness will likely lead to increased reporting, I doubt that increased awareness is adequate to 
explain the several fold increase in SF notifications.  I guess what I am pointing out is that this section 
of the discussion seems to be grasping at straws.  I would prefer to see a frank acknowledgement 
that the cause is simply unknown and that the underlying cause of SF is unknown or poorly 
understood.  On the other hand, I doubt that there has been a dramatic change in the human host 
population in the UK especially among children, that is to say that I doubt children under the age of 
10, the most affected group, have all in the last 3 years become injection drug users which would 
explain the increase in SF.  I doubt that the environment has changed in the UK in such a way as to 
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only favor GAS scarlet fever infections and none of the other multitude of GAS disease 
manifestations.  
Thus the only thing that is left to my mind that has the ability to change this rapidly, is the pathogen.  
I acknowledge that in the end of the paragraph these weak logical straw man alternative hypotheses 
are rejected.  I just think it is meaningless to create these logical straw men just so they can be 
knocked down and would like to see something intellectually deeper if possible. 
 
RESPONSE: we acknowledge that the rise could not credibly be explained by a change in notification 
practice but do feel that the reasoning allowing us to dismiss this needs to be spelt out to rebuff any 
such suggestions. It is also important for readers to not consider the notifications as representing 
the true incidence of scarlet fever as underreporting is demonstrated in our paper. However, we 
have amended the text  so that this issue is covered much more succinctly. 
 
Reviewer #3: Lamanghi et al. report on the ongoing scarlet fever outbreak in the UK. The emergence 
of scarlet fever in the UK and South-East Asia (from 2011) is a very surprising clinical finding, and this 
current work provides a very clear picture of disease burden across the UK and the impact of disease. 
This information and the description of the UK outbreak in detail is of great importance and will aid 
the health systems of other countries in terms of monitoring for the spread of this outbreak, and 
prudent public health measures that can be implemented. 
 
Comments for the authors consideration. 
 
1. Page 2, line 14 - Suggest also providing percent incidence of other 3 emm types (emm12, emm1 
and emm4)along with that reported for emm3 (40%). 
 
RESPONSE: thank you for this suggestion. Additional information now included. 
 
2. Page 3, line 9-10 - Is it possible to outline what the most common scarlet fever emm types were 
present in Vietnam, South Korea, Hong Kong and mainland China (emm12 and emm1?). 
 
RESPONSE: this could be included in the Introduction but as outlined in the Discussion in the context 
of our own findings, I’m not sure it would be helpful to detail here too.  
 
3. Page 4, line 4 - "England is the first northern hemisphere country...". Vietnam, South Korea, Hong 
Kong and mainland China are all north of the equator. YSuggest you change northern to western 
hemisphere. 
 
RESPONSE: thank you for pointing out this oversight on our part. We’ve amended the text as 
suggested. 
 
4. Page 9, Figure 4 - Would it be possible to map scarlet fever incidence side by side with a map of UK 
population density? Clearly, London does not come up as a "hot spot", but such a side by side 
comparison would underline this point. 
 
RESPONSE: whilst we concur with the reviewer’s view that areas of high population density do not 
appear to have the highest rates, this has not been assessed in our study. To do so would require a 
fairly complex analysis as it would need to factor in density of primary school-aged children and 
exploration of other influencing factors (such as scale of analysis, distribution of schools and 
nurseries). Such an analysis should be considered for the future but we feel it is outside the scope of 
the present study. 
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5. Page 11, line 1 - Are the 303 throat isolates reported here the same as the 303 scarlet fever 
isolates reported by Chalker et al. (BMC Genomics, reference 11)? If so, please make this clear by 
referencing this section of the manuscript.  
 
RESPONSE: yes, these are the same isolates discussed in the BMC Genomics paper (ref 11). 
References aren’t usually included within the Results section. We have already referenced the paper 
in the Methods (p7). 
 
Is there any evidence of the transfer of strains (eg. emm12 and emm1) or genetic elements (phage 
and ICE) from SE Asia into the UK? In particular, it would be illuminative to report the carriage rates 
of SSA and SpeC for each of the emm types characterized here (particularly the more common emm4, 
emm3, emm1 and emm12). This information would extend this current work (PCR screen for these 
genes if these are not the genome sequence isolates from BMC Genomics), as it has been reported 
that SSA and SpeC are carried by a variety of phage in the SE Asia outbreak and that these genes are 
associated with scarlet fever causing GAS strains in SE Asia (emm12 and emm1). This type of 
comparative analysis would very much assist the field in helping to determine the importance of 
these superantigen genes and their association with scarlet fever in the UK. Note that SSA, SpeC and 
SpeA have been found associated with scarlet fever isolates in a previous European study (Silva-Costa 
et al. 2014 Pediatric Infectious Disease Journal 33: 306-310). 
 
RESPONSE: The carriage of phage is detailed in ref 11 – however this is not detailed by emm type. As 
mentioned on p14, the emm12 bacterial strain lineage in Hong Kong was not seen in UK strains and 
we further note that the Hong Kong scarlet fever upsurge was not attributed to one lineage but 
associated with several lineages. Phage sequence with homology to the HKU360.ssa phage was 
found in emm12 strains in the UK, however, these bacterial strains were distinguishable to those 
from Hong Kong. Provision of phage content by lineage is outside the scope of this study. In light of 
your comments, we have however expanded the Discussion slightly to mention the finding of the 
HKU360.ssa phage in the UK and to note that further study is needed in this area (p14). 
 
 
6. Page 12 line 3 - "Whilst there is no obvious connection between the situation in the UK and the Far 
East, a link cannot be wholly excluded without further understanding of the drivers behind these 
changes." Firstly, the 2 most common emm types causing scarlet fever in SE Asia are emm12 and 
emm1. Secondly, Chalker et al (BMC Genomics, reference 11) reports that 43/63 emm12 UK scarlet 
fever isolates contains the HKU360.ssa phage found in Hong Kong isolates. Thre seems to be 
examples of links at least between a subset of strains causing scarlet fever from the UK and SE Asia. I 
would thus suggest that if the point above (Page 11, line 1) is addressed, other links may become 
apparent, or alternatively not so. In any case, the statement about no obvious connection should be 
toned down. 
 
RESPONSE: we have reworded this sentence to indicate that there is no clear connection between 
the HK and UK situation as feel this is the case, given the lack of common ancestry in our respective 
strain lineages. The fact that we see some of the same emm types is not surprising as these are 
common types and/or classically associated with scarlet fever. 
 
7. Page 12, last line - "Of note, the particular (emm12) lineage associated with the surge in scarlet 
fever in Hong Kong was absent from the isolates collected in the UK (11, 20)." Whilst this statement is 
technically correct, reference 20 (Tse et al. JID 2012) was the first genome sequence of a single SE 
Asia scarlet fever isolate which contains the HKU.vir phage which encodes SSA and SpeC. However, 
follow up reports in 2015 of the SE Asia outbreak describe a number of SSA encoding emm12 (Davies 
et al. Nature Genetics 47: 84-87) and emm1 phage (Ben Zakour Scientific Reports 5: 15877). Chalker 
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et al. (BMC Genomics, reference 11) notes the absence of HKU.vir phage in UK emm12 scarlet fever 
isolates, but reports that 43/63 emm12 UK scarlet fever isolates contains the HKU360.ssa phage 
found in Hong Kong isolates. Thus, this section of the discussion needs to be reworked to address 
these key considerations. 
 
RESPONSE: we have amended the Discussion text to draw attention to the presence of this phage in 
the UK and HK strains (see p14). This now reads as follows: 
 
“Of note, the particular (emm12) lineage isolated from a number of patients during the surge in scarlet 
fever in Hong Kong was absent from the isolates collected in the UK. Interestingly, phage with 
sequence homology to a phage detected in Hong Kong (HKU360.ssa) was found in emm12 strains in 
the UK, albeit in a minority of isolates.
11,21,22
 Further research is needed to explore the movement of 
mobile genetic elements between bacterial lineages and the influence of such elements on disease 
manifestation at a population level. Nonetheless, in the absence of clearly defined microbial 
characteristics that can explain the current epidemic, the hunt for further explanations for the rise in 
scarlet fever goes on.” 
 
Reviewer #4: The study reported that after decades of decreasing scarlet fever incidence, a dramatic 
increase was observed in England beginning in 2014. Although some similar studies have been 
published in Hong Kong, mainland China and other regions, this study might fill up the gaps in the 
incidence trend of scarlet fever in recent years in England. Hence there is value in conducting a study 
as submitted. However, there are some areas that warrant explanation. 
  
MAJOR comments 
1. Page 2: In the background and introduction, this study aimed to identify potential causes for the 
dramatic increase in scarlet fever incidence. However, the results and discussions were not enough to 
explain the potential causes. Please add more explanations in the Discussion section. 
 
RESPONSE: we’re not clear what additional information the reviewer is requesting we add to the 
Discussion. We have outlined clearly the investigative lines pursued and conclusions drawn from our 
study and the wider context, and stipulated that the reasons for the rise are as yet unanswered. 
 
2. Page 8: In the first paragraph of the Results section, the authors reported that "over the course of 
2014, 15,637 scarlet fever notifications were made". But in the third paragraph of the Results 
section, they reported "50% 7,157/14,385 were male". The total number of scarlet fever notifications 
in 2014 was different in the paragraph. Please specify and revise the sentences. 
 
RESPONSE: the longitudinal analysis of trends is based on data for England and Wales as we cannot 
split data for the two countries for the early part of this time series. This is stated in the first 
paragraph of the Results, in the Methods and in the title of Figure 1. In contrast, all the detailed 
analyses are based on data for England only, hence the difference in the denominators. 
 
3. In the second and third paragraph of Page 9, the authors only analyzed the data from 2014 to 
2016. It would be better to add the data before 2014 when there was an upsurge in scarlet fever. So 
the authors can further discuss the differences across years and provide further evidences for better 
explanation. 
 
RESPONSE: we agree with this idea and in fact both paragraphs already detail the changes in 
hospitalisation which occurred during the upsurge period (2014 onwards) compared to 2013.  
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4. In the last paragraph of Page 10, the authors stated that the increasing trend in scarlet fever 
incidence was reported from 2014 to 2016, but an elevation in iGAS infections was only found in 
2015/16. Please make a detailed discussion on this finding. 
 
RESPONSE: this finding is mentioned in the discussion although rather briefly. We’ve added some 
further text to outline that investigations are ongoing to assess this rise. Our initial investigations 
suggest that the prolonged influenza season may have played a role in elevating iGAS incidence but 
too soon for us to high. 
 
5. In the last paragraph of Page 12, the authors attempted to explain the potential causes for the 
dramatic increase in scarlet fever incidence. They should provide more details about the previous 
findings in England. 
 
RESPONSE: we’re unclear as to what this refers to and feel pertinent prior information regarding SF 
the UK has been adequately addressed earlier in the paper.  
 
6. Tables and figures: It is confusing that some data were presented by calendar year (from week 1 to 
week 52), and some by epidemic season (from week 37 to week 36). Please explain why or revise the 
data. 
 
RESPONSE: the weekly incidence data are presented by season (week 37 to 36) to ensure the 
seasonal rise and fall are captured in a continuous time series. Using calendar year would split this 
across two series making it difficult to follow without jumping from one line to another. We have 
amended the use of the word ‘year’ to specifically refer to calendar year to minimise ambiguity and 
provided a description in the Figure legend of which months these seasonal start/end weeks fall. 
 
7. Table 1 and supplementary table 1: It would be better to present data in other years (such as years 
before 2013, 2015 and 2016) in the table.  
 
RESPONSE: undertaking this assessment to assess the cause of the hospitalisation was incredibly 
time consuming giving the large array of detailed clinical data accompanying each admission. As our 
objective was to assess whether there was a proportionate or disproportionate rise in admissions for 
management of complications, especially rheumatic fever, we feel including the two years is 
sufficient. Figure 5 provides data for scarlet fever hospital admissions in additional years. 
 
8. Figure 3&4: Only data from 2014 was presented, what about other years before and after 2014. 
9. Supplementary figure 1, the data from 2013 should be presented in the figure. 
 
RESPONSE: The age distribution in subsequent years was exactly as per 2014 (which also matched 
prior years) so not particularly important for readers to see. The geographical distribution did alter 
between the years as described in the Results (p10) and shown in Supplementary Table 2. Additional 
maps (or age distributions) could be added but would push the maximum number of illustrations 
beyond the journal maximum (6).  
  
MINOR comments 
10. The order numbers of the figures in Page 4-7 of SUPPLEMENTARY TABLES AND FIGURES may be 
wrong. Please check carefully. 
 
RESPONSE: thank you for drawing our attention to this. Supplementary Fig numbers now corrected. 
 
Reviewer #5: Increasing rates of scarlet fever in British Isles.  
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Overall this paper is well written but quite wordy.  It could be shortened substantially.  The authors 
have provided the ID world an interesting observed phenomenon of increasing rates of scarlet fever 
(SF) over the last few years in England/Wales from 8 cases up to 33 cases per 100,000 population. 
The data seems to have some validity  with the seasonality (March peak) and primary age of those 
infected being pediatric patients.  
  
Major criticisms: 
-abstract—hyperbole-I would not call this a public health "priority" as rates of hospitalizations and 
complications and deaths from SF were basically stable over time.   
 
RESPONSE: we do not agree that we have exaggerated the public health importance of our findings.  
The paper reflects the classification of the incident by Public Health England as a Level 3 incident, 
one level below that used for major public health threats such as a flu pandemic. The population 
rates of hospitalisation were far from stable during this upsurge but increased as shown in the 
paper. Whilst we’re not aware of any associated deaths to date, the economic burden is substantial 
and the concern of the public tremendous, leading to persistent media interest. A search on the 
internet will reveal the scale of this activity and concern. 
 
 
-p3 para 1. Was SF disease itself a common  cause of death in the past actually? Or was it a marker 
for eventual acute rheumatic fever [ARF] pre antibiotics. Now that antibiotics are available,  deaths 
from SF remain exceedingly rare, as Abs prevent ARF.    Scarlet fever itself is merely a strep throat 
infection where  the strep pathogen secretes an exotoxin causing a very specific rash.  
 
RESPONSE: I would agree that the scarlet fever of today is characterised by a strep throat 
accompanied by an array of symptoms thought to be due to exotoxin production. However, the 
scarlet fever epidemics of the 19th and 20th century, well studied in both Europe and North America, 
represent an entirely different form of scarlet fever, which included life-threatening ‘toxic’ and 
‘septic’ forms. Whilst reports of sequelae suggestive of ARF were made, these were by no means 
ubiquitous amongst scarlet fever deaths, many of which occurred in the acute phase of scarlet fever, 
consistent with a picture of fulminant sepsis.  References 1-3 and 8 describe the incremental 
changes which saw the severe forms of the condition become less common. We don’t, furthermore, 
consider that availability of antibiotics explain the drop in severity of these diseases as the incidence 
fell long before then, primarily towards the end of the 1800s. A change in pathogenicity of 
circulating strains could plausibly account for this change, as mentioned in the paper. 
 
P6. Para 1. Was this "signs" and  symptoms?  The signs are what clinch the diagnosis, as the 
symptoms are generic and the history of a rash is entirely nonspecific.  
 
This method section is the area where the data loses reliability. "with or without laboratory 
confirmation" is worrisome. The data on SF are only as good as the reliability of the diagnosis, which 
cn be confirmed in part by the testing for strep! Were there any recommended or  specific criteria 
given for the SF rash to be identified?  Yes, an experienced pediatrician can typically make the 
diagnosis readily without strep testing, but I would be very hesitant  to say the same for an NP, GP or 
nurse or parent.  
 
RESPONSE: as the notifications were only accepted from clinicians, diagnoses would have been 
made on the basis of signs and symptoms exhibited by the patients on clinical examination, with or 
without microbiological confirmation. We have amended the paper to reflect this (p7). 
Communications were issued during the upsurge period to assist clinicians in their diagnosis and 
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many articles published in reputable primary care journals reminding GPs of the signs of infection 
(e.g. refs 26 and 27). 
 
Whilst we accept that there is the potential for some misdiagnosis, this is unlikely to be happening to 
a large extent given the characteristic signs of scarlet fever. Whilst we don’t advocate routine 
swabbing for scarlet fever (or pharyngitis) in this country, only where necessary for differential 
diagnosis, our national laboratory surveillance shows a doubling in numbers of patients with GAS 
throat isolates between 2013 and 2014, with numbers increasing progressively into 2015 and 2016, 
in line with the rise in scarlet fever notifications.  
 
However, we also know that 3 other pathogens can cause a scarlatini rash, further obfuscating the 
data here.  They are arcanobacterium hemolyticum,  mononucleosis (it just rarely appears on the 
groin), and most importantly , S. aureus such as related to impetigo or surgical scarlet fever, which 
we see with some frequency in private practice. [Skin Findings of Staphylococcus aureus Toxin-
mediated Infection in Relation to Toxin Encoding Genes. Courjon, Johan MD*†‡§; Hubiche, Thomas 
MD†; Phan, Alice MD, PhD‡; Tristan, Anne PharmD, PhD§; Bès, Michele PhD§; Vandenesch, François 
MD, PhD§; Etienne, Jerome MD, PhD§; Del Giudice, Pascal MD†; Gillet, Yves MD§¶Pediatric 
Infectious Disease Journal: July 2013 - Volume 32 - Issue 7 - p 727-730]   
 
RESPONSE: as per our comments above, whilst we cannot demonstrate the accuracy of the all the 
notifications, the impact of any misdiagnosis on the study can only be very limited. Firstly, we would 
contend that the rate of misdiagnosis is likely to be small as the nature of rash and accompanying 
signs are reasonably specific. Within our epidemiological context, misdiagnosis as measles is more 
likely and has been subject to investigation which has identified a very small number of 
misdiagnoses in older children (>15y), so not within the age range predominantly diagnosed with 
scarlet fever. We have a number of clinicians (paediatricians and ID physicians) on the Incident 
Management Team who have intimate knowledge of our surveillance and healthcare delivery 
systems and have provided input into the interpretation of data available to us. This input was also 
informed by what they and their professional networks were reporting and seeing on the ground as 
all are clinically active.  
 
Secondly, the epidemiological characteristics of our study cases fit with scarlet fever and don’t fit 
with impetigo (entirely different seasonal pattern) or Arcanobacterium hemolyticum and infectious 
mononucleosis, both of which primarily affect older children and young adults. Any misdiagnoses 
could of course result in both over and under-notification as they would apply in both directions.  
 
Thus practitioners could have been using primarily  a penicillin or a macrolide. Aand if the SF rash 
were caused by S. aureus, then eradication would not occur, and the staph pathogen could both 
cause the SF rash and an impetigo, and thus be related to much more dissemination of SF disease.  
 
Also, what is the percentage of penicillin, macrolide, and cephalosporin use for GAS also in the 
region, as high rates of failure for GAS pharyngitis have been reported for both azithromycin (30-
50%) and  amoxicillin (20-30%)( summary in Block, Pediatric Annals Jan. 2014)?   
Thus could it be that they are witnessing more antibiotic failures, more macrolide use,  or an 
epidemic of MRSA or other pathogen?   
 
RESPONSE: we agree that inadequate treatment will further propagate the scarlet fever upsurge that 
we’re currently witnessing. For this reason, our widely disseminated communications to front line 
medical staff and the general public have emphasised the need to seek medical attention and 
antibiotic treatment if scarlet fever is diagnosed. We have been actively monitoring antibiotic 
resistance in GAS throat isolates throughout this period to ensure any changes are identified and 
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clinical guidance amended as needed. No such longitudinal changes were noted although these 
findings are as yet unpublished.  
 
 
Furthermore, the rash has a very specific pattern: fine, maculo-papular salmon or light red; heaviest 
and starting in the groin, then axilla, then abdomen and trunk and antecubital, and sometimes 
extending further on the legs and arms, rarely on the back or hands and feet. It may also cause major 
peeling of the groin and hands and feet as the rash subsides over the ensuing week, which often 
confirms the suspicion of SF. It may or may not be itchy. It is not serpiginous, urticarial or 
morbilliform or blotchy..   how much detail was needed in order to make the diagnosis by the 
practitioner, or was it just someone's best guess for the less experienced? Thus, could it be that more 
children are being seen by NPs than ever (like the "NP urgent care centers popping up everywhere in 
the USA) in England, who lack clinical experience?  
 
RESPONSE: we agree with the reviewer that the clinical features are distinctive and as such, the 
reviewer’s observations chime with our response above that misdiagnosis at scale is unlikely. With 
regard to provision of care, there have been no widespread changes in how primary care is delivered 
in England. Even if there were changes, and such changes theoretically led to poorer diagnostic 
practices, we cannot see how logically these could translate into wide scale over-notification of one 
specific disease as opposed to a proliferation in misdiagnoses of an array of childhood rash illnesses. 
 
How much testing was performed for strep, and which test is typically used in England? Is the rapid 
ADT usually or culture  used, and how frequently do practitioners employ testing in your country?  In 
the USA, managed care groups strongly push for routine strep testing. If ADT or culture is nearly 
uniform in this region, then the data gains credibility. 
 
RESPONSE: GPs in the UK do not routinely take throat samples to diagnose strep throat or scarlet 
fever, however in our communications and guidelines, we have emphasised the importance of 
taking samples if there is any doubt over the aetiology of the rash.  The rise in GAS throat isolates 
from 2014 onwards provides further evidence that the rise in scarlet fever is real. 
 
Minor comments: 
-p9. do you have any other ideas as to why patients are admitted for strep throat or uri? Dehydration 
or high fever or what?  
 
RESPONSE: this would be useful information to collect at a future point but not available in our 
study.  
 
-p10. without culture confirmation, I would be leery about calling puerperal sepsis GAS and not GBBS.   
 
RESPONSE: puerperal sepsis is how the local hospital coded this patient’s diagnosis and as such, 
there is no translation on our part. We make no inference as to the aetiology of the infection beyond 
identifying the temporal association of the admission and the scarlet fever notification.  
 
-p11. So out of 15637 cases, only 303 had a + culture.  Is this small sample size due to lack of 
obtaining specimens as a routine, or use of ADTs. Please add this to the other limitations of this 
study. Any claims about serotyping may be tenuous.  You might mention the Silva-Costa article in 
PIDJ 2014 about emm typing and SF.  
 
RESPONSE: as described in the Methods, the isolates assessed were drawn from a sampling scheme. 
They in no way represent the totality of isolates from all scarlet fever cases in England. The 
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Discussion notes the potential limitations of these isolates in terms of geographical coverage and 
possible bias in severity of presentations in these patients. Thank you for the suggestion regarding 
the Silva-Costa paper. However, as this is a single centre study conducted during 2002-08, I’m not 
sure how the findings assist us in interpreting our current situation. 
 
-also the SF rate still seems under reported. In our pediatric private practice with over 3000 positive 
ADTs over a 15 month period, I suspect we saw over a hundred cases of SF in this time frame among 
an entire cohort of about 10000 children mostly from age 3 to 12 y.o. (Block Pediatric Annals January 
2014)   
 
RESPONSE: thank you for drawing attention to this article. The denominator cited in the article (the 
cohort) appears to be based on children attending your clinic undergoing rapid antigen testing for 
GAS. As such, they do not represent the totality of children in a given geographical location but a 
subset likely to have a considerably higher rate of GAS/scarlet fever diagnosis by virtue of having 
signs and symptoms leading to the testing. A direct comparison of incidence with our population-
based data is therefore not meaningful. 
 
-p. 13. In your discussion you may want to point out the following influenza association as well: In 
2009, studies in Utah showed a marked increase in invasive GAS infections following influenza [39]. 
Similarly during the 2010 seasonal influenza epidemic in Great Britain, there was a marked increase 
in the prevalence of GAS pneumonia and bacteremia; this phenomenon was associated with a 
greater than 50 percent mortality [40]. This could explain more as to why you are so  concerned 
about GAS SF, even though your data showed no increase in severe complications or mortality.   
 
RESPONSE: we’re aware that heightened influenza activity is linked to an increase in severe GAS 
presentations and we are currently involved in the study mentioned above (UK). However, we don’t 
see a plausible connection between influenza activity and the scarlet fever upsurge as the 2013/14 
flu season (during which our escalation began) had low levels activity similar to that in the preceding 
years. 
 
-the last sentence on the page is quite convoluted and barely makes sense.  
 
RESPONSE: we’ve reformulated this sentence to improve ease of understanding. 
 
P14. Please explain why a simple infection like SF without any complications, led to such a high rate 
of hospitalizations for simple pharyngitis and uri and AOM.  Unusual  severe complications were rare 
in this population. . 
 
RESPONSE: we can’t answer that beyond describing the clinical codes associated with the 
admissions. Of note, and as mentioned in the Results, the hospital admissions were of varying 
lengths and didn’t necessarily involve an overnight stay in hospital. We’ve amended the text in the 
Discussion to remind readers of this. 
 
P15. Your references are quite skimpy, as 11/26 were either bulletins or public health notices. I do not 
find this acceptable for this journal.  How about some more real back ground data, such as peer 
reviewed articles or reviews on SF. 
 
RESPONSE: We’re at a loss to see how the reviewer counted 11 public health notices/bulletins. 
There are 2 public health bulletins included, one being an article in EuroSurveillance which is a peer 
reviewed journal.  In truth, there is little recent relevant literature aside from a wealth of papers 
16 
from the Far East (many of which are cited), on scarlet fever. As such, there isn’t a great body of 
recent literature to draw on. 
